Cargando…
Neoantigens in Hematologic Malignancies
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, i...
Autores principales: | Biernacki, Melinda A., Bleakley, Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033457/ https://www.ncbi.nlm.nih.gov/pubmed/32117272 http://dx.doi.org/10.3389/fimmu.2020.00121 |
Ejemplares similares
-
Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019) -
Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies
por: Tubb, Vanessa M., et al.
Publicado: (2018) -
Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies
por: Saini, Sunil Kumar, et al.
Publicado: (2022) -
Determinants for Neoantigen Identification
por: Garcia-Garijo, Andrea, et al.
Publicado: (2019) -
The Neoantigen Landscape of Mycosis Fungoides
por: Sivanand, Arunima, et al.
Publicado: (2020)